Clinical Trial

Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 25, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy, safety, and immunogenicity of PEG-G-CSF Injection (Kexing Biopharmaceutical Co., Ltd.) for the prevention of neutropenia after chemotherapy, using the PEG-G-CSF Injection ( Neulasta®, Amgen Europe B.V.) as a positive control.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-27.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-11-23
Trial Details
NCT Number NCT06711523
Lead Sponsor Kexing Biopharm Co., Ltd.
Conditions Neutropenia, Chemotherapy-Induced Febrile, Breast Neoplasm Female
Enrollment 250 participants
Start Date 2025-01-09
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-25